A Phase 2/3 interventional study of fMRI and Indirect calorimetry in Obesity, sponsored by Rennes University Hospital. Completed at 1 site in France. Open to female participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by Rennes University Hospital · Phase 2/3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 475 studies in Obesity with a site in France — 111 open to participants now, 127 under way, 25 of them phase 3. Obesity · France.
Among the 475 studies in Obesity with a site in France, this one is the 238th largest by enrollment of the 354 interventional ones that give a count, is one of 30 that started in 2018, is one of 3 in phase 2/3, and was the 230th registered.
11,529 studies on the registry are indexed under Obesity; 2,035 are open to participants now.
Browse Obesity studies →111 of the 475 studies in Obesity with a site in France are open now. Recruiting first, the newest first:
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques · Sites in France
Ages 50–75
AstraZeneca · Sites in France, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–75
Universite du Littoral Cote d'Opale · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 166 take children under 18; 488 take healthy volunteers.
This study: 30 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
475 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 21 · Phase 3 61 · Phase 4 14
First in 2001; this study’s year is marked. 30 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 67 across 9,010 interventional studies indexed under Obesity.
Median enrollment 80 across the 354 interventional studies, 133 across the 121 observational. Of the 295 that completed or were terminated, 16 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 475 have an industry lead sponsor. The 10 most frequent:
Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.
Rennes University Hospital has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
30 of the studies in Obesity with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT03516968Phase 3Hospices Civils de LyonMonthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents | 2027-03 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
Add all 30 to your calendar (.ics) → With an account.
Among the 475 studies in Obesity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Identification of the cerebral fMRI phenotype of obese patients with FA in cognitive task context based on food choice making
Obesity is a worldwide epidemic associated with many complications. The treatment of obesity is a failure if it does not take into account eating disorders. Among them, food addictions seem to be frequent among obese patients. Clinical diagnosis and therapeutic approaches depend on presence of these FA. Moreover, eating disorders are associated with visible brain abnormalities in fMRI but the cerebral fMRI phenotype of FA is not known.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire. Three clinical visits will be realized in less than two months
Device: fMRI · Device: Indirect calorimetry · Device: Bioimpedance · Biological: Lipid profile, glucose, HBA1c, metabolomic analysis · Behavioral: YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)
Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire. Three clinical visits will be realized in less than two months
Device: fMRI · Device: Indirect calorimetry · Device: Bioimpedance · Biological: Lipid profile, glucose, HBA1c, metabolomic analysis · Behavioral: YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)
Brain MRI
Resting energy expenditure
Measurement of body composition
Blood sample
Questionnaires to characterize eating habits and depression
Significant change in brain activity of the prefrontal cortex (area involved in the inhibitory control of food intake) measured by modification of BOLD (Blood-Oxygen-Level-Dependent) signal in fMRI during a cognitive task based on food choice making
Time frame: Month 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2018 to primary completion in Sep 2021, 40 months.
Of 33 non-industry phase 2/3 interventional studies under Obesity, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 53. This study's 40 months is below that.
Counting every sponsor, half of 36 studies reached it within 47 months; a quarter within 30 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.